Drugmakers Novo Nordisk and Eli Lilly are vying for a large slab of the weight loss medications market, which analysts reckon could be worth $100 bln by 2031. In this Viewsroom podcast, Breakingviews columnists discuss how investor optimism in a booming market is unwarranted.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Breakingviews - Amazon applies therapy to retailAmazon.com is rolling out a new program to sell toys through mobile games while pushing incentives of $10 to get customers to pick up their stuff rather than have it delivered. Little wonder why. Rising costs and customers battered by inflation are hampering Amazon’s efforts to get its retail division on a path to sustainable profitability. These measures are unlikely to help.
Lire la suite »
Breakingviews - Omaha man sails into Florida’s imperfect stormIt’s easy to see Nebraskan Warren Buffett turning into Florida man – geographically speaking more so than the irrational internet meme version. The Sunshine State’s insurance industry is a mess, and Hurricane Ian only compounded the problems. This imperfect storm suits the Berkshire Hathaway CEO’s investing style.
Lire la suite »
Breakingviews - Aramco’s dividend largesse contains a hard logicSaudi Aramco’s first-quarter net profit may be off by a fifth compared with a year earlier, but it’s also being more generous to shareholders. On top of an existing dividend programme that saw the company hand out $20 billion to investors between January and March, the $2 trillion oil behemoth said on Tuesday it plans to introduce a “performance-linked” payout policy that aims to distribute between 50% and 70% of annual free cash flow. That could work out to up to $18 billion a year, Royal Bank of Canada analysts reckon.
Lire la suite »
Breakingviews - ValueAct loses its temper in 7-ElevenValueAct Capital’s chief Mason Morfit prefers to chide undervalued conglomerates behind closed doors. But Seven & i has so provoked him, his firm has launched a PowerPoint flame war that calls for chief Ryuichi Isaka’s head. The upcoming shareholder vote at the end of the month will test how aggressive activists can get in Japan.
Lire la suite »
Breakingviews - Rebuilding Ukraine depends on luring private moneyOleksandr Gryban is already thinking of the moment when Ukraine can build again. The war-torn country’s 41-year-old deputy economy minister is aware that Kyiv needs to avoid exhausting the goodwill of its allies, who last year financed the government to the tune of $32 billion in public funds. But the real challenge is to convince sceptical private investors both at home and abroad that Ukraine is a good destination for their cash.
Lire la suite »
Breakingviews - Swedish drugmaker finds alluring poison pillSweden’s rare disease drug maker is experiencing unfortunate deal side effects. On Wednesday, shares in Swedish Orphan Biovitrum (SOBI) fell 15% after it announced a plan to buy CTI BioPharma , a specialist in rare blood cancers, for $1.7 billion.
Lire la suite »